Radiolabeled
peptides hold promise as diagnostic/therapeutic targeting vectors for specific human
cancers. We report the design and development of a targeting vector, [(64)Cu-
NOTA-8-Aoc-BBN(7-14)NH(2)] (
NOTA = 1,4,7-
triazacyclononane-1,4,7-triacetic
acid, 8-Aoc = 8-aminooctanoic
acid, and BBN =
bombesin), having very high selectivity and affinity for the
gastrin-releasing peptide receptor (GRPr). GRPrs are expressed on a variety of human
cancers, including breast, lung, pancreatic, and prostate, making this a viable approach toward site-directed localization or
therapy of these human diseases. In this study, [
NOTA-X-BBN(7-14)NH(2)] conjugates were synthesized, where X = a specific pharmacokinetic modifier. The IC(50) of [
NOTA-8-Aoc-BBN(7-14)NH(2)] was determined by a competitive displacement cell-binding assay in PC-3 human
prostate cancer cells using (125)I-[Tyr(4)]-BBN as the displacement
ligand. An IC(50) of 3.1 +/- 0.5 nM was obtained, demonstrating high binding affinity of [
NOTA-8-Aoc-BBN] for the GRPr. [(64)Cu-
NOTA-X-BBN] conjugates were prepared by the reaction of (64)CuCl(2) with
peptides in buffered aqueous
solution. In vivo studies of [(64)Cu-
NOTA-8-Aoc-BBN(7-14)NH(2)] in
tumor-bearing PC-3 mouse models indicated very high affinity of conjugate for the GRPr. Uptake of conjugate in
tumor was 3.58 +/- 0.70% injected dose (ID) per g at 1 h postintravenous injection (p.i.). Minimal accumulation of radioactivity in liver tissue (1.58 +/- 0.40% ID per g, 1 h p.i.) is indicative of rapid renal-urinary excretion and suggests very high in vivo kinetic stability of [(64)Cu-
NOTA-8-Aoc-BBN(7-14)NH(2)] with little or no in vivo dissociation of (64)Cu(2+) from the
NOTA chelator. Kidney accumulation at 1 h p.i. was 3.79 +/- 1.09% ID per g. Molecular imaging studies in GRPr-expressing
tumor models produced high-contrast, high-quality micro-positron-emission tomography images.